Hansa Biopharma: increase in number of shares and votes

BioSpace | 2024-05-03 | 翻译由动脉网AI生成，点击反馈



可切换为仅中文







LUND, Sweden, May 3, 2024 /PRNewswire/ -- Hansa Biopharma AB (publ), ('Hansa' or the 'Company') (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby the number of votes increased with 10,474,740 and the share capital increased with SEK 10,474,740..

瑞典隆德，2024年5月3日/PRNewswire/-Hansa Biopharma AB（publ），（“Hansa”或“公司”）（STO:HNSA）今天宣布，公司注册股本以及股份和投票数已于2024年4月12日通过发行10474740股新普通股而增加，其中投票数增加了10474740，股本增加了10474740瑞典克朗。。

As of today, the total number of registered shares of the company amounts to 65,508,981, whereof 63,146,536 are ordinary shares and 2,362,445 are class C shares. As of today, the number of votes in the company amounts to 63,382,780.5, and the registered share capital amounts to SEK 65,508,981.

截至今日，公司注册股份总数为65508981股，其中普通股63146536股，C类股2362445股。截至今日，公司的投票数为63382780.5，注册股本为65508981瑞典克朗。

The information in the press release is information that Hansa Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on May 3, 2024 at 08:00 (CEST).

新闻稿中的信息是Hansa Biopharma AB（publ）根据欧盟市场滥用法规有义务公开的信息。该信息于2024年5月3日08:00（CEST）通过上述联系人的机构提交出版。

Contacts for more information:

联系人了解更多信息：

Evan Ballantyne, Chief Financial Officer

首席财务官Evan Ballantyne

ir@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs

Stephanie Kenney，全球企业事务副总裁

media@hansabiopharma.com

This information was brought to you by Cision http://news.cision.com

此信息由Cision提供给您http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma--increase-in-number-of-shares-and-votes,c3972696